Saltar al contenido
PivotalWire
Lunes 12 oct 2026SEC · NASDAQ biomédico

Portada›Jueves 11 de diciembre de 2025

Biomédicas del NASDAQ ante la SEC, jueves 11 de diciembre de 2025

Los 38 documentos que 31 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. CTNMContineum Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
  2. FULCFulcrum Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
  3. NXTCNextCure, Inc.424B1Nueva emisión de acciones con precioEDGAR
    En el documentoContrasplit de accionestexto original ▸…text thereof, copies of each of which have previously been filed as exhibits to our filings with the SEC. Reverse Stock Split On July 14, 2025 at 12:01 am Eastern time (the “Effective Time”), the Company effected a one-for- twelve (1:12) reverse stock split (the “Reverse Stock Split”) of the Company’s common stock. The Reverse Stock Split affected all shares of Company’s common stock outstanding immediately prior to the Effective Time. No fractional shares…
  4. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 10, 2025, the closing sale price per warrant of our Public Warrants was $0.19. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
  5. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 10, 2025, the closing sale price per warrant of our Public Warrants was $0.19. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
  6. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 10, 2025, the closing sale price per warrant of our Public Warrants was $0.19. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
  7. SHPHShuttle Pharmaceuticals Holdings, Inc.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…incorporated herein in reliance upon such report given on the authority of such firm as experts in accounting and auditing. The report of Forvis Mazars, LLP contains an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern. 9 INFORMATION INCORPORATED BY REFERENCE The SEC allows us to “incorporate by reference” information that we file with them. Incorporation by reference allows us to disclose important information to you…
  8. TNYATenaya Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…shares of common stock issuable upon exercise of pre-funded warrants sold in this offering; and • shares of common stock issuable upon exercise of Warrants sold in this offering. On August 10, 2022, we entered into a sales agreement with Leerink Partners LLC with respect to an “at-the-market” (ATM) program pursuant to which we may sell up to $75.0 million of shares of our common stock (the ATM Program). As of the date of this prospectus supplement, we have sold an aggregate of 1,358,333 shares of our common…
  9. WVEWave Life Sciences, Inc.424B5Nueva emisión de acciones con precioEDGAR
  10. ARWRARROWHEAD PHARMACEUTICALS, INC.S-3ASRCapacidad de emisión registradaEDGAR
  11. OLMAOlema Pharmaceuticals, Inc.S-3ASRCapacidad de emisión registradaEDGAR
  12. TCRTAlaunos Therapeutics, Inc.424B8Prospecto de reventa de tenedoresEDGAR

Participaciones y control

  1. IRDOpus Genetics, Inc.SC 13D/ACambio en participación significativaEDGAR
  2. KYMRKymera Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. CLYMClimb Bio, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  2. RNTXRein Therapeutics, Inc.8-KFin de acuerdo materialEDGAR
  3. SRPTSarepta Therapeutics, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  4. TNYATenaya Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
    En el documentoParada clínica impuesta por la FDAtexto original ▸…reference in such filing. Item 8.01 Other Events. Following proactive correspondence with the FDA relating to future development plans for TN-201, on November 7, 2025, the Company announced that the FDA placed MyPEAK-1 on clinical hold requesting an amendment to the protocol primarily to standardize activities related to patient monitoring and management of the immunosuppression regimen across trial sites. The Company worked swiftly…
  5. VBIOValion Bio, Inc.8-KFin de acuerdo materialEDGAR
  6. ABUSArbutus Biopharma Corp8-KOtros hechos relevantesEDGAR
  7. ALNYALNYLAM PHARMACEUTICALS, INC.8-KOtros hechos relevantesEDGAR
  8. BCRXBIOCRYST PHARMACEUTICALS INC8-KCambio en el consejo o la direcciónEDGAR
  9. BCTXBriaCell Therapeutics Corp.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…continue to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company not be able to…
    En el documentoContrasplit de accionestexto original ▸…capital The authorized share capital consists of an unlimited number of common shares with no par value. b. Issued share capital (i) Reverse Stock Split: On January 3, 2025, the Company’s board of directors approved a reverse stock split of the Company’s common shares on a 1-for-15 basis, which became effective on January 24, 2025 and on August 25, 2025 (the “Effective Date”), the Company effected a reverse stock split of its common shares…
  10. BEAMBeam Therapeutics Inc.8-KCompra o venta de activos completadaEDGAR
  11. CRBPCorbus Pharmaceuticals Holdings, Inc.8-KOtros hechos relevantesEDGAR
  12. CTNMContineum Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
  13. CVKDCadrenal Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
    En el documentoAcuerdo de licencia o colaboracióntexto original ▸…the License Agreement) related to the development and commercialization of 4-((2-Hydroxy-3-MethoxyBenzyl)Amino) Benzenesulfonamide Derivatives as 12-Lipoxygenase Inhibitors (“12-LOX”). Pursuant to the License Agreement, the Seller agreed to pay Licensor certain royalties and certain milestone payments related to the first Licensed Product or Licensed Service developed, some of which will be assumed by the Company as part of the Assumed Liabilities. The term “Licensed…
    En el documentoDesignación de medicamento huérfanotexto original ▸…thromboembolic events. These events have become a preferred, clinically meaningful endpoint for regulators, clinicians, and payers, given the rising rates observed in current HIT populations. VLX-1005 has received Orphan Drug Designation (ODD) and Fast Track designation from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation therapeutics targeting 12-LOX are also…
    En el documentoDesignación de vía rápida (Fast Track)texto original ▸…thromboembolic events. These events have become a preferred, clinically meaningful endpoint for regulators, clinicians, and payers, given the rising rates observed in current HIT populations. VLX-1005 has received Orphan Drug Designation (ODD) and Fast Track designation from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation therapeutics targeting 12-LOX are also under development for type 1 diabetes…
  14. ELVNEnliven Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…Fair holds a B.S. from the University of Michigan and an M.B.A. from Columbia Business School. There are no arrangements or understandings between Mr. Fair and any other persons pursuant to which he was appointed President and Chief Executive Officer and director. There are no family relationships between Mr. Fair and any director or executive officer of the Company, and Mr. Fair does not have any direct or indirect material interest in any transaction…
  15. FULCFulcrum Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
  16. IMVTImmunovant, Inc.8-KOtros hechos relevantesEDGAR
  17. LPCNLipocine Inc.8-KOtros hechos relevantesEDGAR
  18. MDGLMADRIGAL PHARMACEUTICALS, INC.8-KCambio en el consejo o la direcciónEDGAR
  19. ORKAOruka Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  20. PRAXPraxis Precision Medicines, Inc.8-KOtros hechos relevantesEDGAR
  21. RYTMRHYTHM PHARMACEUTICALS, INC.8-KOtros hechos relevantesEDGAR
  22. SCLXScilex Holding Co8-KCambio en el consejo o la direcciónEDGAR
  23. WVEWave Life Sciences, Inc.8-KNuevo acuerdo materialEDGAR

Juntas de accionistas

  1. ARTLARTELO BIOSCIENCES, INC.DEF 14AConvocatoria de junta de accionistasEDGAR

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.